Acurx Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
ACXP$1.060.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Years Ended | ||||||
| · · December 31, | ||||||
| · · 2023 · · 2022 | ||||||
| | | | | | | |
| Cash Flow from Operating Activities: · · | ||||||
| Net Loss | | $(14,577,768) | | $(12,092,776) | ||
| Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities: | | | | |||
| Share-Based Compensation | | 3,206,527 | | 2,871,681 | ||
| Share-Based Payments to Vendors | | 559,583 | | 430,680 | ||
| (Increase)/Decrease in: | | | ||||
| Other Receivable | | | (129,159) | | | — |
| Prepaid Expenses | | 159,179 | | 30,349 | ||
| Accounts Payable and Accrued Expenses | | | 980,753 | | | 1,217,776 |
| Net Cash Used in Operating Activities | | | (9,800,885) | | | (7,542,290) |
| | | | | | | |
| Cash Flow from Financing Activities: | | | ||||
| Proceeds from Registered Direct Offering, net of issuance costs | | | 3,543,612 | | | 3,695,182 |
| Pre-funded Warrant Exercise | | | 73 | | | 13 |
| Warrant Exercise | | | 2,218,999 | | | — |
| Proceeds from At-the-Market Offering, net of issuance costs | | | 2,400,638 | | | — |
| Net Cash Provided by Financing Activities | | | 8,163,322 | | | 3,695,195 |
| Net Decrease in Cash | | (1,637,563) | | (3,847,095) | ||
| Cash at Beginning of Year | | | 9,111,751 | | | 12,958,846 |
| Cash at End of Year | | $7,474,188 | | $9,111,751 | ||
| | | | ||||
| SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES | | | | | | |
| 2023 Registered Direct offering costs (Note 4) | | $1,990,153 | | $— | ||
| Warrants issued in connection with 2022 offerings (Note 4) | | $— | | $171,409 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.